Edition:
United States

Celltrion Pharm Inc (068760.KQ)

068760.KQ on KOSDAQ - Korea Secs Dealers Association Quotation

18,950.00KRW
22 Sep 2017
Change (% chg)

₩-600.00 (-3.07%)
Prev Close
₩19,550.00
Open
₩19,500.00
Day's High
₩19,500.00
Day's Low
₩18,900.00
Volume
173,404
Avg. Vol
116,123
52-wk High
₩25,350.00
52-wk Low
₩18,150.00

Chart for

About

Celltrion Pharm Inc. is a Korea-based company engaged in the manufacture and marketing of pharmaceuticals. The Company’s products include hepatotonics, analgesics, antipyretics, anti-inflammatory drugs, antihistamines, respiratory apparatus drugs, circularly system drugs, digestives and stomachic drugs, hormone disease drugs,... (more)
No analyst recommendations are available for .

Overall

Beta: 0.73
Market Cap(Mil.): ₩629,953.00
Shares Outstanding(Mil.): 33.24
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.67 16.08
EPS (TTM): -- -- --
ROI: -- 15.12 14.60
ROE: -- 16.35 14.03

Samsung Bioepis wins EU endorsement for first Herceptin copy

* Bioepis could receive 4 EU biosimilar approvals in two years

Sep 15 2017

U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

JERUSALEM Teva Pharmaceutical Industries and South Korea's Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

Jul 31 2017

U.S. FDA to review Teva and Celltrion's cancer biosimilar drug

JERUSALEM, July 31 Teva Pharmaceutical Industries and South Korea's Celltrion said on Monday the U.S. Food and Drug Administration has accepted for review a biologics application for a biosimilar drug to treat breast cancer.

Jul 31 2017

BRIEF-Celltrion and Teva announce FDA acceptance of BLA for CT-P10

* Celltrion and teva announce u.s. Fda acceptance of biologics license application for proposed biosimilar to rituxan® (rituximab)

Jun 29 2017

Earnings vs. Estimates

No consensus analysis data available.